Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Diet, exercise, and behavioral changes remain the foundation of PCOS care
Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record
The industry has consolidated and some manufacturers have little incentive to solve shortages because cheap generics generate thin profits
Actyl-L-carnitine (ALCAR) : Cest la forme privilgier pour prendre soin de son cerveau
Summary: Rybelsus is the first oral GLP-1 receptor agonist (semaglutide) licensed in the UK for treating type 2 diabetes in adults, offering a convenient tablet alternative to injectable GLP-1 therapies
US$ 25.06
US$ 24.72
US$ 20.73
US$ 27.83
US$ 21.10
US$ 24.70
US$ 28.03
US$ 24.10
US$ 22.09
US$ 22.47
